Antibe Therapeutics Provides Update on Its Acute Pain Drug ATB-352

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company’s pipeline, as described in the CEO Letter of April 2014. These studies have demonstrated that ATB-352 potently inhibits the production of pain-signalling chemicals (prostaglandins) in rats, but does not produce significant ulceration in the stomach or intestine, even at very high doses. In the same study, administration of the painkiller ketoprofen caused severe and extensive intestinal ulceration and bleeding.

“ATB-352 has a novel mechanism of action,” said Antibe’s Chief Science Officer, Dr. John Wallace. “The small amounts of hydrogen sulfide that are released from this drug exert a potent protective effect in the stomach and intestine. This drug was designed to address a substantial unmet medical need, and a market exceeding $2 billion annually.”

ATB-352 is a potent pain-killer intended for use in the short-term treatment of conditions characterized by severe pain, including that associated with herniated discs, gout, ankylosing spondylitis, migraines, traumatic injuries, muscle aches, post-surgical pain, toothache and menstrual cramps. Dan Legault, Antibe’s CEO remarked, “For many patients, there are only two viable options for treatment of severe pain: traditional non-steroidal anti-inflammatory drugs (NSAIDs), which can cause severe gastrointestinal bleeding, and opiates, which carry the risks of addiction and abuse. ATB-352 is intended to provide an important third option to this large group of patients.”

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s ATB-346 targets the global need for safer non-steroidal anti-inflammatory drugs (NSAIDs).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Antibe Therapeutics Inc.Dan Legault, 416-473 4095Chief Executive [e-mail]